나이관련황반변성(AMD) 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Age Related Macular Degeneration (AMD) Therapeutics Market size is expected to reach USD 29.81 Billion in 2034 from USD 15.57 Billion (2025) growing at a CAGR of 7.48% during 2026-2034.

The global age-related macular degeneration (AMD) therapeutics market is expanding as the prevalence of vision-related disorders increases among the aging population. AMD is one of the leading causes of vision loss among older adults, affecting the macula and impairing central vision. The growing elderly population worldwide and rising awareness about early diagnosis and treatment options are driving demand for effective AMD therapeutics.

Advancements in biotechnology and pharmaceutical research are playing a crucial role in the development of innovative AMD treatments. Anti-VEGF therapies have become a widely adopted treatment approach, helping slow disease progression and improve patient outcomes. Additionally, increasing investments in clinical research and the introduction of new drug delivery systems are contributing to the growth of the AMD therapeutics market.

Looking ahead, the AMD therapeutics market is expected to benefit from the development of gene therapies, long-acting injectable drugs, and advanced treatment approaches. Pharmaceutical companies are focusing on innovative therapies aimed at improving treatment efficacy and reducing dosing frequency. Moreover, improved screening programs and expanding healthcare access in developing regions are expected to support the continued growth of the AMD therapeutics market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other Products

By Disease Type

• Wet AMD
• Dry AMD

By Age Group

• 50-64 Years
• 65-74 Years
• 75 and Above

By Distribution Channel

• Hospital Pharmacies
• Specialty and Retail Pharmacies
• E-Commerce

COMPANIES PROFILED

• Amgen Inc, Apellis Pharmaceuticals Inc, Bayer AG, Biocon Biologics Ltd, Biogen Inc, Celltrion Inc, F HoffmannLa Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sandoz Group AG, STADA Arzneimittel AG, Xbrane Biopharma AB
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Eylea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lucentis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Beovu Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Vabysmo Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Syfovre Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Avastin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Wet AMD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Dry AMD Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. 50-64 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. 65-74 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. 75 and Above Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. E-Commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Disease Type
  • 8.2.3 By Age Group
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Disease Type
  • 8.3.3 By Age Group
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Disease Type
  • 8.4.3 By Age Group
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Disease Type
  • 8.5.3 By Age Group
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Disease Type
  • 8.6.3 By Age Group
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen Inc
  • 10.2.2 Apellis Pharmaceuticals Inc
  • 10.2.3 Bayer AG
  • 10.2.4 Biocon Biologics Ltd
  • 10.2.5 Biogen Inc
  • 10.2.6 Celltrion Inc
  • 10.2.7 F. Hoffmann-La Roche Ltd
  • 10.2.8 Formycon AG
  • 10.2.9 Novartis AG
  • 10.2.10 Pfizer Inc
  • 10.2.11 Regeneron Pharmaceuticals Inc
  • 10.2.12 Sandoz Group AG
  • 10.2.13 STADA Arzneimittel AG
  • 10.2.14 Xbrane Biopharma AB